Is your thumb or hand joint a good fit for ChondroFiller injection?

ChondroFiller injection works best when there is a focal, contained cartilage defect in the thumb CMC or another small hand joint — one where the surrounding bone and cartilage remain sufficiently intact to support a regenerative scaffold. Patients who fit this profile and have already tried corticosteroids, hyaluronic acid, or PRP without lasting relief, yet are not ready for permanent surgery such as trapeziectomy, sit in the clinical sweet spot the procedure is designed to serve.

The main exclusion is advanced, widespread joint destruction — the kind of bone-on-bone disease where little cartilage surface remains to anchor and recruit cells. Hip arthroscopy data reinforce this boundary: patients with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly following cartilage scaffold treatment, while those with focal, earlier-stage lesions achieved good-to-excellent results at three to five years. Active infection in or near the joint, systemic immunosuppression, and poorly controlled diabetes are additional contraindications regardless of disease stage.

Both early-stage (Eaton-Littler grade I–II) and more advanced (grade III–IV) thumb CMC disease are represented in the two prospective clinical studies underpinning ChondroFiller injection — so the procedure is not restricted to the mildest presentations alone. The benefit pattern does differ meaningfully between these groups, however, and that distinction is covered in a later section.

For patients comparing their options, ChondroFiller injection is an outpatient, image-guided procedure, not surgery. There is no general anaesthetic, no theatre booking, and no permanent alteration to the joint's anatomy — a material difference from trapeziectomy, which removes the trapezium bone entirely and is not reversible.

How ChondroFiller injection works inside a small joint

Once the needle is positioned inside the joint space under ultrasound guidance, ChondroFiller injection is introduced as a liquid. Within the defect, it undergoes rapid in-situ gelation, forming a porous three-dimensional collagen scaffold — acellular at the point of injection, meaning no cells are harvested from the patient beforehand.

The scaffold does not repair the defect by itself. Instead, it acts as a chemotactic matrix, drawing the patient's own progenitor cells in from the surrounding synovium and subchondral bone — a process termed acellular matrix-induced chondrogenesis. Ex vivo experiments measured a 2.4-fold increase in DNA content within ChondroFiller-filled defects by day 14, confirming that active cellular migration into the scaffold occurs rather than passive cavity filling.

Delivery into small joints is technically straightforward: G20–21 fine-gauge cannulas are sufficient, and a 2025 prospective wrist study of 25 patients with chondral defects following distal radius fracture confirmed the approach is viable at this scale. Volume precision is critical, however. That study established 0.2–0.3 mL per defect as the appropriate dose, and found that overfilling — rather than flush placement level with the adjacent cartilage surface — was the sole factor associated with fibrous tissue formation rather than hyaline-like repair. Because outcome depends on precise image-guided placement, clinician experience with small-joint technique directly influences results.

What the clinical evidence shows for thumb and hand joints

The strongest published evidence for ChondroFiller injection in the hand comes from two prospective trapeziometacarpal (TMC) osteoarthritis studies by Corain and colleagues.

The larger and longer — published in 2025 in a PMC-indexed journal (PMC12213533), 64 patients, Eaton-Littler grade 1–4 — measured NRS pain scores, DASH functional questionnaires, and grip and pinch strength at intervals beyond two years after a single ultrasound-guided injection. All outcomes showed statistically significant improvement (P<0.001), sustained across the full follow-up period. No adverse events were reported in any of the 64 patients.

A 2023 prospective study by the same group (43 patients, six-month follow-up) produced consistent findings across the same measures — NRS pain, DASH, grip, and pincer strength — at both 30 days and six months. Together the two studies form a coherent dataset: the earlier paper establishes responsiveness; the later one confirms it holds over time.

The thumb CMC joint is currently the only small hand joint with multi-study prospective data. ChondroFiller injection is offered clinically for focal defects in the fingers, elbow, AC joint, toes, and TMJ, and a 2025 wrist study provided technical feasibility data for small-joint delivery — but that study addressed chondral defects following distal radius fracture, not thumb OA, and should not be read as equivalent clinical evidence for those sites. Randomised controlled trial data for the thumb and other small hand joints do not yet exist; the Corain studies are prospective and peer-reviewed, but not randomised. Across both studies — 107 patients in total — zero adverse events were reported, a meaningful safety signal for a single-injection outpatient procedure.

How disease stage shapes what you can realistically expect

Disease stage in thumb CMC osteoarthritis does not simply determine whether ChondroFiller injection is appropriate — it also shapes which dimension of improvement a patient is most likely to notice first.

The Corain 2025 study (64 patients, Eaton-Littler grade 1–4, more than two years of follow-up) found that patients at grades 1–2 showed greater gains in objective grip and pinch strength. Those at grades 3–4 showed proportionally larger improvement in DASH functional disability scores. Both groups improved across both measures; the difference lies in where the most meaningful change fell — a pattern the 2023 study (43 patients, six-month follow-up) corroborated across the same staging groups.

That distinction has a practical use before consultation. For a patient at an earlier stage, the realistic expectation is measurable recovery in hand strength alongside pain reduction. For a patient at a more advanced stage, the more prominent gain is likely to be functional — doing more without being limited by pain — rather than restoration of grip force to previous levels. Neither outcome is inferior; they reflect the different starting points and cartilage reserves at each stage.

One boundary warrants clarity: Eaton-Littler grade 3–4 does not automatically indicate unsuitability. A higher-grade joint that still contains a focal, bounded defect is a different clinical scenario from one where bone-on-bone contact has destroyed the articular surface comprehensively — and that distinction is best explored at a clinical assessment. The strength-versus-function split in the data is the clearest guide to what stage-specific benefit looks like in practice.

Where ChondroFiller injection sits in the treatment pathway

The 2024 meta-analysis of ten randomised controlled trials found no meaningful difference between corticosteroid and hyaluronic acid injections for thumb OA pain, grip strength, or function. A 2025 double-blind trial in 90 patients added PRP to that picture — a single injection performed no better than saline. Standard steroid injections at the thumb base typically provide four to five months of relief, with diminishing returns on repeat.

None of this removes those options from the pathway. Symptom management serves a genuine purpose, and each of these modalities features in standard care for a reason. The structural limitation is the relevant point: they address the experience of pain without altering the defect driving it. For a patient whose benefit has become progressively shorter-lived with each injection course, that distinction becomes clinically meaningful.

Trapeziectomy — surgical removal of the trapezium — remains the established definitive intervention for advanced thumb CMC osteoarthritis. It is effective and durable. It is also irreversible: once the bone is removed, the anatomical architecture of the thumb base is permanently altered.

ChondroFiller injection occupies the structural-but-non-surgical space between these two points. As an outpatient ultrasound-guided injection, it targets the focal cartilage defect directly through a regenerative scaffold mechanism rather than masking symptoms. The anatomy is preserved intact. It is not a guaranteed alternative to surgery in every case — suitability turns on the defect characteristics and stage of disease confirmed at clinical assessment — but for the right candidate it represents a step that palliative injections cannot offer and that stops well short of permanent surgical change.

After the injection: recovery, access, and next steps in London

The scaffold's initial mechanical instability under load shapes what happens immediately after the injection. Biomechanical data show that cyclic loading before stable integration is achieved risks disrupting the repair process, so bracing and activity restriction are part of the treatment itself — not precautionary extras that patients can set aside once the discomfort fades. For small hand joints, a restricted-use period of roughly one to two weeks is typical; the exact duration is calibrated to the joint treated and the patient's day-to-day demands at the assessment stage.

Technique quality has a direct bearing on outcome, and the 2025 wrist series made this concrete. Overfilling a defect — even modestly — produced fibrous tissue formation at follow-up arthroscopy, while flush application, with the gel level with the adjacent cartilage surface, was free of that complication. The volume used per defect in that study was 0.2–0.3 mL; precision in delivery, not generous dosing, is what distinguishes a good structural result. Continuous image guidance and careful volume control are the quality markers worth raising at any pre-procedure consultation.

UK pricing for ultrasound-guided ChondroFiller injection in thumb and small hand joints sits at approximately £2,100–£2,800, inclusive of the product and image guidance. Health insurers do not routinely cover this treatment; itemised invoices can be provided for independent claims, and confirming coverage in advance is advisable.

ChondroFiller injection for thumb and small hand joints is available in the UK at the London Cartilage Clinic on Harley Street, the UK's certified delivery centre for the product. An initial assessment — covering imaging review, disease staging, and candidacy — is the recommended starting point; further information is available at londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: cohort study 12–60 month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Influence of cartilage defects and collagen gel on integrity of corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z